OncoMatch/Clinical Trials/NCT07069335
A Bioequivalence Study to Evaluate Pharmacokinetics and Safety of BR2022 and BR2022-1 in Patients With Deleterious or Suspected Deleterious Germline BRCA-Mutated Advanced Ovarian Cancer
Is NCT07069335 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies Olaparib 150 MG for ovarian cancer.
Treatment: Olaparib 150 MG — This was a multicenter, open-label, randomized, crossover bioequivalence study to evaluate the pharmacokinetics and safety of BR2022 and BR2022-1 in Patients with deleterious or suspected deleterious germline BRCA-mutated advanced ovarian cancer.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Biomarker criteria
Required: BRCA1 deleterious or suspected deleterious germline or somatic mutation
deleterious or suspected deleterious germline or somatic BRCA-mutated
Required: BRCA2 deleterious or suspected deleterious germline or somatic mutation
deleterious or suspected deleterious germline or somatic BRCA-mutated
Disease stage
Metastatic disease required
advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer
Prior therapy
Must have received: PARP inhibitor (olaparib)
have been taking stable doses of olaparib for more than 3 months before screening
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify